Home About Us R&D Services Careers News & Events Responsibility Contact Us  
     
 
  R&D Services
   
  Project Procedure and Management  
  line2  
  Target Identification, Validation and Enablement  
  line2  
  Biomarker Discovery  
  line2  
  Assay Development  
  line2  
  Pre-clinical Drug Development  
  line2  
  Standard Cell and Molecular  
  line2  
  Other Services  
 
 
 
  Target Identification, Validation and Enablement

Target selection is the earliest phase of R&D in the drug discovery and development (DD&D) value chain, which includes target identification, validation and enablement for compound testing. Making the right choice of targets at the beginning of the DD&D process is the crucial first step down the long and expensive road of creating innovative medicines.


ARL has core competencies in providing consultancy and R&D services in the following areas:
  • Screening processes utilizing different assay principles and technologies to discover new drug targets (and potential anti-targets) in cancer by cell-based or phenotypic methods

  • Validation data package (in vitro, cell-based and in vivo) for potential targets identified from the screens will comprise data on target biology, genetic networks and pathways that provide information to support target's linkage to disease and likely cellular and molecular mechanisms of action (MOA). MOA studies may include structural biology

  • In vivo studies using mouse models, including studies using xenografts or patient-derived solid tumours for oncology; physiological gene functions by transgenic methods; pre-clinical pharmacology

  • For enablement of new targets for compound screening, new assays will be developed or may be transferred to ARL from clients


 
 
 
 
Home | Sitemap | Contact Us  
Copyright © 2010 Acumen Research Laboratories | All rights reserved